Show simple item record

dc.contributor.authorRymaszewska, Joanna
dc.contributor.authorLion, Katarzyna M
dc.contributor.authorPawlik-Sobecka, Lilla
dc.contributor.authorPawlowski, Tomasz
dc.contributor.authorSzczesniak, Dorota
dc.contributor.authorTrypka, Elzbieta
dc.contributor.authorRymaszewska, Julia E
dc.contributor.authorZablocka, Agnieszka
dc.contributor.authorStanczykiewicz, Bartlomiej
dc.date.accessioned2020-06-10T05:53:05Z
dc.date.available2020-06-10T05:53:05Z
dc.date.issued2020
dc.identifier.issn1664-0640
dc.identifier.doi10.3389/fpsyt.2020.00522
dc.identifier.urihttp://hdl.handle.net/10072/394511
dc.description.abstractIntroduction: Accumulating evidence indicates the effectiveness of cryogenic temperature interventions in rheumatoid arthritis, ankylosing spondylitis, fibromyalgia, multiple sclerosis, and chronic low back pain. The application of whole-body cryotherapy (WBC) in psychiatric aspects of medicine was also noted. Nevertheless, the exact mechanisms explaining the beneficial effect of WBC on mood disorders remain unclear. The study aimed to assess the efficacy of repetitive short exposure to extremely low temperatures (WBC) on mood, quality of life as well as on biochemical measures among people diagnosed with depressive episode undergoing pharmacological treatment. Materials and Methods: Prospective randomized, double-blind sham-controlled protocol was used. The study enrolled 92 medically stable adults (aged 20–73 years) with a diagnosis of a depressive episode. The participants were randomly allocated and exposed to 10 whole-body cryotherapy (WBC) sessions (−110°C till −160°C [the experimental group (EG)] or to low, but not cryogenic temperatures −50°C [the control group (CG)]. Thirty participants in the EG and 26 in CG completed the whole study. The primary outcome measures were depressive symptoms evaluated with the Beck Depression Inventory-II (BDI-II) as well as the Hamilton Depression Rating Scale (HAM-D 17). The quality of life, quality of sexual life, acceptance of the disease and self-reported mood, vitality, and sleep quality were assessed as secondary outcome measures. The study was registered at Australian New Zealand Clinical Trials Registry (ACTRN12619001600134). Results: The results show evidence for a statistically significant difference in the clinical assessment of depressive symptoms according to HAM-D 17 scale (T4 by group interaction p=0.02), BDI-II (T2 time by group interaction p=0.01), cognitive-affective BDI dimension (T4 by group interaction p=0.00), and somatic BDI dimension (T4 by group interaction p=0.028). Significant improvement was also noticed in life quality (p < 0.05), self-assessed mood (p=0.035), and disease acceptance (p=0.007). There were no statistically significant changes related to sexual satisfaction, self-assessed vitality, and sleep (p > 0.05). Conclusions: Whole-body cryotherapy is a useful method to improve standard pharmacological treatment. The WBC intervention reduces mental health deterioration, especially in mood disorders, such as depression, and can be beneficial for well-being and quality of life.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.relation.ispartofpagefrom522:1
dc.relation.ispartofpageto522:13
dc.relation.ispartofjournalFrontiers in Psychiatry
dc.relation.ispartofvolume11
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchPsychology
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1117
dc.subject.fieldofresearchcode1701
dc.titleEfficacy of the Whole-Body Cryotherapy as Add-on Therapy to Pharmacological Treatment of Depression—A Randomized Controlled Trial
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationRymaszewska, J; Lion, KM; Pawlik-Sobecka, L; Pawłowski, T; Szcześniak, D; Trypka, E; Rymaszewska, JE; Zabłocka, A; Stanczykiewicz, B, Efficacy of the Whole-Body Cryotherapy as Add-on Therapy to Pharmacological Treatment of Depression—A Randomized Controlled Trial, Frontiers in Psychiatry, 11, pp. 522:1-522:13
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2020-06-09T21:38:21Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2020 Rymaszewska, Lion, Pawlik-Sobecka, Pawłowski, Szcześniak, Trypka, Rymaszewska, Zabłocka and Stanczykiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
gro.hasfulltextFull Text
gro.griffith.authorLion, Katarzyna M.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record